Information Provided By: 
Fly News Breaks for June 11, 2019
ZTS
Jun 11, 2019 | 05:58 EDT
Barclays analyst Balaji Prasad started Zoetis with an Overweight rating and $120 price target. The analyst launched coverage of 20 U.S. Specialty Pharmaceuticals with a Neutral industry view. He placed importance on cash flows and companies' ability to manage leverage and improve balance sheets.
News For ZTS From the Last 2 Days
ZTS
Apr 23, 2024 | 05:05 EDT
Barclays lowered the firm's price target on Zoetis to $230 from $260 and keeps an Overweight rating on the shares ahead of the Q1 report. The analyst expects the Q1 reports to provide continuing evidence of improvement in generics and biosimilars for the specialty pharmaceuticals group.
